Fig. 1: Elevated INTS13 expression predicts poor prognosis in cervical cancer and correlates with key clinicopathological features.

Box plots illustrating the differential expression of INTS13 in cervical tissues versus various histological subtypes of cervical cancer (adenocarcinoma [AC], adenosquamous carcinoma [ASC], and squamous cell carcinoma [SCC]) based on TCGA data (A). Box plots showing the expression levels of INTS13 across different T-stages, N-stages, and M-stages within the TCGA cervical cancer cohort (B–D). A receiver operating characteristic (ROC) curve demonstrating the diagnostic performance of INTS13 for cervical cancer in the TCGA dataset (E). Kaplan-Meier overall survival curves comparing patients with high versus low INTS13 expression across the entire TCGA cervical cancer cohort (F), or within the adenocarcinoma (AC) (G) and squamous cell carcinoma (SCC) (H) histological subtypes from the TCGA dataset. Box plots illustrating the relationship between INTS13 expression and patient body weight categories from TCGA data (I, J). Kaplan-Meier overall survival curves comparing patients with high versus low INTS13 expression stratified by body weight subgroups from the TCGA dataset (K, L). “TPM” stands for transcripts per million. “AUC” stands for area under the curve. “CI” stands for confidence interval. “HR” stands for hazard rate. “TPR” stands for true positive rate. “FPR” stands for false positive rate. “BMI” stands for body mass index. Data are presented as mean ± standard deviation (SD). * P < 0.05. ** P < 0. 01.